Virtu Financial LLC Acquires 167 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Virtu Financial LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,669 shares of the company’s stock after purchasing an additional 167 shares during the quarter. Virtu Financial LLC’s holdings in Medpace were worth $1,551,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. R Squared Ltd bought a new position in shares of Medpace during the 4th quarter worth approximately $30,000. SBI Securities Co. Ltd. bought a new position in shares of Medpace during the 4th quarter worth approximately $31,000. Stone House Investment Management LLC bought a new position in shares of Medpace during the 3rd quarter worth approximately $33,000. Jones Financial Companies Lllp raised its stake in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after acquiring an additional 110 shares in the last quarter. Finally, Lindbrook Capital LLC raised its stake in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after acquiring an additional 29 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

MEDP stock opened at $324.23 on Friday. The firm’s fifty day simple moving average is $337.72 and its 200-day simple moving average is $339.82. The company has a market capitalization of $9.88 billion, a P/E ratio of 25.67, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.